Alteration in Claudin–4 Contributes to Airway Inflammation and Responsiveness in Asthma

Pureun-Haneul Lee,¹ Byeong-Gon Kim,¹ Sun-Hye Lee,¹ June-Hyuck Lee,¹ Sung-Woo Park,¹ Do-Jin Kim,¹ Choon-Sik Park,¹ George D. Leikauf,² An-Soo Jang¹*

1Division of Allergy and Respiratory Medicine, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Korea
2Department of Environmental and Occupational Health, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA

INTRODUCTION

Asthma is a chronic inflammatory disorder affecting 300 million individuals worldwide.¹⁻³ Symptoms of asthma, including episodic airway obstruction, airway hyperresponsiveness (AHR), and reduced lung function, are due to chronic airway inflammation and underlying structural changes in the airway wall.⁴⁻⁷ The bronchial epithelium is constantly exposed to a wide range of environmental materials present in inhaled air, including noxious gases and anthropogenic/natural particulates, such as gas and particles from car emissions, tobacco smoke, pollen, animal dander, and pathogens.⁸ As a fully differentiated, pseudostatified mucociliary epithelium, the bronchial epithelium protects the internal milieu of the lung from these agents by forming a physical barrier involving secretion of mucus, which traps inhaled particles that can be cleared by the mucociliary escalator.⁸ The bronchial epithelium as the initial cell in contact with the environment also plays a pivotal role in immune surveillance and appropriate activation of immune effector cells and antigen presenting cells in the presence of pathogens or other danger signals.⁹

The airway epithelium closely exposed to the external environment plays an important role as a physical barrier and a modulator of allergic response, and leads to allergic inflammation.²,⁹ Barrier dysfunction in the lung causes allergens to affect the epithelium and produce various cytokines that mediate airway inflammation.¹⁰⁻¹³ Epithelial barriers consist of airway surface liquids, mucus, and apical junctional complexes that form between neighboring cells.¹³ Tight junctions (TJs) act as a barrier to the paracellular transport of ions, solutes, and water, as well as cells, and function as...
a fence that divides apical and basolateral domains of plasma membranes.\textsuperscript{14,15} TJ cleavage and repair occur following exposure of epithelial cells to allergens, suggesting that disruption of lung epithelium permeability barrier by allergens may be an important event in allergic sensitization and asthma.\textsuperscript{16-18}

Claudins are structural molecules of TJs, and different claudins (about 27 claudins) are responsible for changes in electrolyte and solute permeability in cell layers.\textsuperscript{19} Claudin-4 has been reported to function as a paracellular sodium barrier and is one of the 4 major claudins expressed in lung alveolar epithelial cells.\textsuperscript{20,21} The role of claudin-4 is studied in lung injury,\textsuperscript{22} cancer,\textsuperscript{23} and fibrosis.\textsuperscript{24} However, the role of claudin-4 in the pathogenesis of asthma is not clear. Up to date, there have been few data about claudin-4 in asthma. Also, this study was to investigate the role of epithelial barrier claudin-4 in the pathogenesis of asthma. Moreover, we also determined claudin-4 levels in blood from asthmatic patients between stable and exacerbated states.

**MATERIALS AND METHODS**

**Patients and Control Subjects**

The biospecimens and clinical data were provided by the biobank of Soonchunhyang University Bucheon Hospital, a member of the Korea Biobank Network. All subjects had a clinical diagnosis of asthma according to the Global Initiative for Asthma (GINA) guidelines.\textsuperscript{2} All subjects underwent standardized assessments that included complete blood cell and differential counts, IgE measurement, chest posteroanterior radiography, allergy skin prick tests, and spirometry. All data were collected at the time of diagnosis, before administration of asthma medication. Exclusion criteria included respiratory infections within 4 weeks of screening, smoking history of >10 packs per year, chronic obstructive pulmonary disease, and parenchymal lung disease apparent on chest radiography.

Normal control subjects were recruited from the spouses of the subjects or members of the general population. Clinical data from patients and control subjects are presented in Table as previously described.\textsuperscript{25}

**Asthma exacerbation**

Asthma exacerbation was defined by the GINA guidelines as episodes of a progressive increase in shortness of breath, cough, wheezing, or chest tightness, or some combinations of these symptoms, accompanied by decreases in expiratory airflow and use of systemic corticosteroids (tablets, suspension, or injection), or an increase from a stable maintenance dose, for at

| Variables | Control subjects | Asthmatic patients |
|-----------|------------------|--------------------|
| No of subjects | 25 | 50 |
| Sex (male/female) | 2/23 | 20/30 |
| Age (of initial visit), (year) | 58.3 ± 6.2 | 54.9 ± 14.1 |
| Onset of asthma: age (year) | 47.06 ± 17.25 |
| Asthma duration (year) | 6.63 ± 3.60 |
| Smoking status (NS/ES/CS) | 25/0/0 | 32/12/6 |
| Cigarettes smoked (pack. year) | 9.0 ± 15.7 |
| Body Mass Index (kg/m\(^2\)) | 24.8 ± 2.61 | 25.4 ± 3.31 |
| Initial Lung function | 115.36 ± 16.59 | 82.42 ± 21.94* |
| FEV1/FVC | 96.66 ± 14.51 | 83.24 ± 17.73* |
| FEV1/FVC | 84.24 ± 6.05 | 73.02 ± 10.88* |
| Stable and exacerbate lung function | 85.43 ± 19.82 | 62.60 ± 18.14* |
| FEV1/FVC | 85.43 ± 19.82 | 62.60 ± 18.14* |
| FEV1/FVC | 73.02 ± 10.88* |
| PC20 (mg/mL) | 9.18 ± 10.37 |
| Total IgE (kU) | 106.63 ± 188.7 | 421.5 ± 699.19* |
| Atopy | 1 (4%) | 21 (42%)* |
| Attack average/y | 3.38 ± 3.24 |
| Blood WBC/μL | 5,587.2 ± 1,268.0 | 7,768.8 ± 3,448.9* |
| Blood eosinophil (%) | 2.73 ± 2.26 | 5.09 ± 4.97* |
| Blood neutrophil (%) | 56.25 ± 10.00 | 54.89 ± 13.03 |

Data are expressed as mean ± SD.

PC20, the concentration of methacholine required to decrease FEV1 by 20%; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; BMI, body mass index; SM, smoker; ES, ex-smoker; NS, non-smoker.

*P<0.01 compared with control subjects; †P<0.05 compared with stable asthmatics.
least 3 days, and a hospitalization or emergency department visit because of asthma requiring systemic corticosteroids. Subjects were followed >2 years.

**Animals and experimental protocol**

All experimental animals used in this study were under a protocol approved by the Institutional Animal Care and Use Committee of Soonchunhyang University Bucheon Hospital. Female, 6 week-old BALB/c mice were sensitized and challenged with OVA as previously described.\(^{25}\) Airway responsiveness was measured, bronchoalveolar lavage fluid (BALF) was collected, and lung tissue was processed for protein, RNA, and hematoxylin and eosin (H&E) stain, and confocal imaging as previously described.\(^{25}\)

**Cell culture**

Primary normal human bronchial epithelial (NHBE) cells (Lonza, Walkersville, MD, USA) were maintained (37°C, pH = 7.4) in serum-free bronchial epithelial cell growth medium (BEGM, Lonza, Walkersville, MD, USA) supplemented with bovine pituitary extract, insulin, hydrocortisone, gentamicin/amphotericin, retinoic acid, transferrin, epinephrine, and human epithelial growth factor. NHBE cells were used before passage 7. Cells were placed in BEGM without supplements for 24 hours and then stimulated with 10 µg/mL house dust mite *Derma-tophagoides pteronyssinus* peptidase 1 (Der p1) (Arthropods of Medical Importance Resource Bank, Institute of Tropical Medicine, Yonsei University, Seoul, Korea) with or without 10 µM dexamethasone (DEX) for 4, 8, or 24 hours. In separated tests, NHBE were transfected with small interfering RNA (siRNA) duplexes designed against claudin-4 or nonspecific siRNA control (Invitrogen, Carlsbad, CA, USA). NHBE cells cultured in 6-well plates were transfected with 100 nM siRNA or negative control using Lipofectamine 2000 (Invitrogen). After 24 hours, cells were treated with 10 µg/mL Der p1 and harvested for PCR analysis. Trans-epithelial electrical resistance measurements (TEER) was used as a measure of TJ formation in NHBE cells as previously described.\(^{25}\)

**Western blot analysis**

Protein extracts of mouse lung tissue were collected as previously described.\(^{25}\) Protein was separated by SDS-PAGE and transferred to polyvinylidene fluoride (PVDF) membranes. The membranes were blocked for 5% bovine serum albumin (BSA) in 0.1% Tween 20 in Tris-buffered saline (TBS) (21°C, 2 hours) and incubated with anti-claudin-4 (1:200, Abcam Inc., Cambridge, MA, USA) (4°C, overnight), followed by horseradish peroxidase (HRP)-conjugated secondary antibodies. Detection was performed using EzWestLumi plus (ATTO Corp, Tokyo, Japan). The relative abundance of protein was determined by quantitative densitometry, and the data were normalized to β-actin (Sigma-Aldrich, St. Louis, MO, USA).

**Immunohistochemistry**

Mouse lung sections were made as previously described,\(^{25}\) and then treated for non-specific binding with 1.5% goat serum and incubated with the anti-claudin-4 (1:100, Abcam). The next day, sections were incubated with avidin and biotinylated horseradish peroxidase macromolecular complex (Vector Laboratories, Burlingame, CA, USA). Color reaction was developed by staining with a liquid DAB + substrate kit (Golden Bridge International Inc., Mukilteo, WA, USA). After immunohistochemical staining, the slides were counterstaining with Herri's hematoxylin for 1 minute. Images were analyzed with the Image J program (National Institutes of Health, Bethesda, MD, USA), and stain density was quantified with an average of claudin-4 arbitrary density numbers from 6-8 fields.

**Immunofluorescence imaging**

Mouse lung sections were made as previously described.\(^{25}\) The sections were blocked for non-specific binding with 1.5% goat serum and incubated with the claudin-4 (1:400, Abcam Inc., Cambridge, MA, USA) +/- TJ protein 1 (TJP1 aka zonula occludens-1, ZO-1) (1:1,000, Santa Cruz Biotech, Santa Cruz, CA, USA), followed by Alexa Fluor 488-conjugated Donkey polyclonal anti-Rabbit IgG (1:1,000, Abcam Inc.) + PE-conjugated goat anti-mouse antibody (1:2,000, BD Bioscience). Nuclei were counterstained with 4,6-diamidino-2-phenylindole (DAPI) (1:1,000, Invitrogen). Sections were observed using a confocal laser scanning microscope (LSM510 META), and images were generated using a Zeiss LSM image browser (Carl Zeiss Microsystems, Thornwood, NY, USA).

**Quantitative real-time polymerase chain reaction (qRT-PCR) analysis**

Total RNA was isolated using TRI REAGENT (Molecular Research Center, Cincinnati, OH, USA). For human cells and mouse lung RNA, cDNA was prepared from 3 µg RNA using oligo(dT), RNase out, and Superscript II reverse transcriptase (Invitrogen) (42°C, 50 minutes), followed by heating inactivation (70°C, 15 minutes). PCR was performed as previously described.\(^{25}\) The following thermal conditions were used: denaturation 94°C×5 minutes, followed by 30 cycles of 94°C×30 seconds, 60°C×30 seconds, and 72°C×30 seconds, and final extension at 72°C×7 minutes. Amplified PCR products were electrophoresed on 1% agarose gels, visualized using an ethidium bromide stain, and analyzed using Kodak EDAS 1D software. Alternatively, qRT-PCR was performed with the StepOneTM Real-Time PCR System (Applied Biosystems, CA, USA). The reactions were prepared with 20 µL of PCR mixture according to the manufacturer’s protocol. The assay-on-demand gene expression products (Applied Biosystems, Inc.) were used to evaluate the mRNA expression levels of claudin-4, interleukin-4 (IL-4), IL-5, and IL-13. Target mRNA levels were normalized to PGK1 levels, and the ratios of normalized mRNA to untreated
Control sample were determined using the comparative Ct (2^\Delta\Delta Ct) method.

**ELISA**

Protein levels of IL-4, IL-5, and IL-13 or claudin-4 in mouse BALF or human plasma were measured by ELISA (R&D Systems, Minneapolis, MN, USA). To compare results from different plates, test sample ODs were adjusted relative to the positive and negative controls. The mean OD of duplicate wells was calculated. The index value of each tested serum was defined by the following formula: index = (OD of tested serum - OD of negative control)/(OD of the positive control - OD of the negative control) \times 100. Low detection limits were set at 2, 7, and 1.5 pg/mL or 0.066 ng/mL for IL-4, IL-5, IL-13, or claudin-4, respectively according to the manufacturer’s recommendation.

**Statistical analysis**

Data are expressed as means ± standard deviation (SD). For nonparametric data, the Mann-Whitney U test was used to assess differences between asthmatic and control groups, and followed by a post hoc test when appropriate (SPSS version 22; SPSS, Chicago, IL, USA). The comparison between stable and exacerbated asthma patients was made within subjects. Correlations were evaluated by calculating Pearson or Spearman correlation coefficients. A Values of P<0.05 (two-sided) was deemed to indicate a statistical significance.

**RESULTS**

**Patients with asthma characteristics**

Fifty asthmatic patients (mean age ± SD, 54.9 ± 14.1 years) and 25 control subjects (mean age ± SD, 58.3 ± 6.2 years) are shown in Table. Initial FEV1% pred, FVC% pred, and FEV1/FVC in patients with asthma significantly lower than in control subjects. Total IgE, atopy, and blood eosinophil proportion were significantly higher in patients with asthma than in control subjects. Body mass index was not different between asthmatic patients and control subjects. Duration of asthma was 6.63 ± 3.60 years and the number of exacerbations per year during the follow-up was 3.38 ± 3.24. FEV1% pred, FVC% pred, and FEV1/FVC were significantly lower in exacerbated asthmatics than in patients with stable asthma. Blood neutrophil proportion was significantly higher in exacerbated asthmatics than in patients with stable asthma.

**Alterations in claudin-4 in patients with asthma**

The mean plasma claudin-4 levels were 0.314 ± 0.044 ng/mL in patients with bronchial asthma and 0.166 ± 0.03 ng/mL in control subjects. The mean plasma claudin-4 levels were 0.451 ± 0.061 ng/mL in exacerbated and 0.314 ± 0.044 ng/mL in patients with stable asthma. Plasma claudin-4 levels were significantly higher in exacerbated patients than in patients with stable asthma (P<0.001, Fig. 1). The plasma claudin-4 levels were significantly higher in patients with stable asthma than in control subjects (P<0.001, Fig. 1). The plasma claudin-4 level was correlated with FEV1% pred (r=-0.245, P=0.006; Fig. 2A), FEV1/FVC (r=0.251, P=0.005; Fig. 2B), eosinophils (r=0.216, P=0.033; Fig. 2C), and total IgE (r=0.284, P=0.001; Fig. 2D).

**OVA-induced inflammation, cytokines, and AHR in mice**

The OVA-sensitized/challenged mice had increased AHR compared to control mice (Fig. 3A). The OVA-sensitized/challenged mice had increased inflammatory cells in BALF compared to control mice (Fig. 3B). IL-4 (36 ±3 pg/mL) and IL-5 (20 ±2 pg/mL) increased in BALF of the OVA-sensitized/challenged mice compared to the control mice (Fig. 3C).

**OVA-induced inflammatory infiltrates and claudin-4 expression transcript/protein in mouse lung**

Lung claudin-4 transcripts (Fig. 3D) and proteins (Fig. 3E) increased in the OVA-sensitized/challenged mice compared to saline-treated mice. On histologic examination, the OVA-sensitized/challenged mice had numerous focal regions with inflammatory cell infiltrates and peribronchial/intraluminal areas of exudation (Fig. 4A). The semi-quantitative value of the inflammatory index from H&E-stained images was increased in the OVA-sensitized/challenged mice. Increased claudin-4 immunohistochemical staining was noted in mononuclear inflammatory cells, endothelial cells, and epithelial cells from the OVA-sensitized/challenged mice (Fig. 4A).

The staining pattern of claudin-4 was altered in NHBE cells of the OVA-sensitized/challenged mice (Fig. 4). Normally, TJ

---

**Fig. 1.** Comparison of plasma claudin-4 level between stable and exacerbated states of asthmatic subjects. *P<0.05; **P<0.005 compare to control; †P<0.05 Stable vs exacerbated asthma.

---

Lee et al. Allergy Asthma Immunol Res. 2018 January;10(1):25-33. https://doi.org/10.4168/aair.2018.10.1.25

http://e-aair.org
form a continuous ring that circumscribes each cell. TJ rings became disrupted in the OVA-sensitized/challenged mice. Confocal image analysis showed significant increases in TJ breaks and the densities of claudin-4 staining (Fig. 4B), suggesting that disruption of the integrity of TJ proteins.

Der p1 increases claudin-4 transcripts and decreases TEER in NHBE

House dust mite Der p1, an aeroallergen with protease activity. To examine whether Der p1 could alter normal airway cells, NHBE cells were treated with 10 μg/mL Der p1 for 4, 8, or 24 hours and claudin-4 transcript levels were measured. Claudin-4 transcripts increased in NHBE cells following 10 μg/mL house dust mite Der p1 treatment for 8 hours (Fig. 5B). Der p1 increased TEER (Fig. 5C). Treatment of the cells with dexamethasone delayed the Der p1-induced TEER. When claudin-4 was decreased by siRNA transfection, the TEER was more decreased than scrambled siRNA control and the Der p1-induced increase in TEER was inhibited. At various time points, cytokine transcripts were increased in NHBE cells following Der p1 treatment (Fig. 6). Treatment of the cells with dexamethasone diminished this effect. The levels of IL-4, IL-5, and IL-13 transcripts were more increased in cells treated with Der p1 and siRNA directed at claudin-4 than in those treated with Der p1.
alone. Treatment of the cells with dexamethasone inhibited this effect.

**DISCUSSION**

Clinical manifestations of asthma, including episodic airway obstruction, airway hyperreactivity (AHR), and reduced lung function, are due to chronic airway inflammation and underlying structural changes in the airway wall. The bronchial epithelium forms a physical barrier of cell-cell junctional complexes and a chemical barrier of mucus which traps and removes inhaled particles by mucociliary clearance. As a gatekeeper to...
Fig. 5. Effects of claudin-4 knockdown on Der p1-induced inflammatory responses. (A) Representative image of siRNA directed claudin-4 in NHBE cells decreased (left panel) transcript determined by PCR (right panel) proteins determined by Western blot. (B) Claudin-4 transcripts increased in NHBE cells following 10 µg/mL Der p1 treatment for 8 hour. This response was inhibited by 10 µM dexamethasone (DEX) treatment. Small interference RNA directed at claudin-4 decreased claudin-4 mRNA. (C) Trans-epithelial electrical resistance (TEER) increased in NHBE cells following 10 µg/mL Der p1 treatment. This response was delayed in NHBE cells treated with 10 µM DEX treatment. siRNA directed at claudin-4 diminished the Der p1-induced increase in TEER. *P<0.05.

Fig. 6. Total RNAs extracted to measure mRNA expression levels of inflammatory cytokines (IL-4, 5, 13) by real-time PCR. (A) Interleukin 4 (IL-4), (B) IL-5 and (C) IL-13 transcript increased in NHBE cells following 10 µg/mL Der p1 treatment for 8 or 24 hours. This response was inhibited by 10 µM DEX treatment. The siRNA directed at claudin-4 increased the response to Derp1 stimulation. *P<0.05.
the environment, the bronchial epithelium plays a pivotal role in immune surveillance and appropriate activation of immune effector cells and antigen-presenting cells by controlling exposure to pathogen-associated molecular pattern molecules (PAMPs). It has been reported that altered lung endothelial CLDN5 expression was associated with airway inflammation in mice, and plasma CLDN5 levels were changed with asthma exacerbation, and asthma therapy can decrease plasma CLDN5 levels. Claudins are structural proteins of TJs, and different claudins are responsible for changes in the electrolyte and solute permeability across cell layers. Claudin-4 can function as a paracellular sodium barrier and is one of the 4 major claudins (claudins-3, -4, 7, and -18) expressed in lung epithelial cells. The role of claudin-4 has been examined in acute lung injury, pulmonary fibrosis, and lung cancer. However, its role in the pathogenesis of asthma is uncertain, and given that epithelial barrier functions can modulate immunity, we examined claudin-4 in this aspect.

To address this issue, 50 asthmatic subjects were recruited from the Genome Research Center for Allergy and Respiratory Diseases in Korea as previously described. Plasma claudin-4 levels were determined during periods when their asthma was controlled or during exacerbations. Initial FEV1 (%predicted), FVC (%predicted), and FEV1/FVC were significantly lower, and total IgE, atopy, and blood eosinophils were significantly greater in subjects with asthma than in those with control subjects. Among the subjects with asthma, FEV1, FVC, and FEV1/FVC were decreased and blood neutrophils were increased during exacerbations than during controlled state. Plasma claudin-4 levels were significantly greater in subjects with asthma than in those with controlled asthma. Plasma claudin-4 levels were increased further during asthma exacerbations. The plasma claudin-4 level was directly correlated with IgE and inversely correlated with FEV1 (%predicted), and FEV1/FVC. Those data suggest that claudin-4 may be useful as an epithelial biomarker for predicting clinical severity in asthmatic patients.

The OVA-sensitized/OVA-challenged mice had increased AHR, BALF inflammatory cells, and BALF cytokines as compared to the OVA-sensitized/saline-treated mice. Lung claudin-4 transcripts and proteins were increased in the OVA-sensitized/OVA-challenged mice compared to the OVA-sensitized/saline-treated mice. The OVA-sensitized/OVA-challenged mice had numerous focal regions with inflammatory cell infiltrates as well as peribronchial and intraluminal areas of exudation. The semiquantitative inflammatory index from H&E-stained images was increased in the OVA-sensitized/challenged mice. Increased claudin-4 immunohistochemical staining was noted in epithelial, mononuclear, and endothelial cells from the OVA-sensitized/OVA-challenged mice. TJs that form a continuous ring that circumscribes individual cells were disrupted in the OVA-sensitized/challenged mice. Confocal image analysis revealed significant increases in TJ disruption and claudin-4 staining. All animal model findings suggest that claudin-4, a TJ protein, is expressed epithelial cells, as well as inflammatory cells and disintegrated in asthma.

House dust mite allergens are important factors for the increasing prevalence of asthma. The lung epithelium forms a barrier that allergens must cross before they cause sensitization. The cysteine proteinase allergen Der p1 from fecal pellets of Dermatophagoides pteronyssinus causes disruption of intercellular TJs, which are the principal components of the epithelial paracellular permeability barrier. Claudin-4 transcripts are increased in NHBE cells following 10 μg/mL Der p1 treatment for 8 hours. At various time points, cytokine transcripts were increased in NHBE cells following Der p1 treatment. Treatment of cells with dexamethasone diminished this effect. The levels of IL-4, IL-5, and IL-13 transcripts were more increased in cells treated with Der p1 and siRNA directed at claudin-4 than in those treated with Der p1 alone. Treatment of cells with dexamethasone inhibited this effect. Der p1 increased in TEER. Treatment of cells with dexamethasone delayed the Der p1-induced TEER. When claudin-4 was decreased by siRNA transfection, TEER was decreased compared to scrambled siRNA control and the Der p1-induced increase in TEER was inhibited.

Inhaled corticosteroids are currently the most effective anti-inflammatory therapy for persistent asthma. Corticosteroid therapy can reduce airway inflammation, airway responsiveness, asthma symptoms, exacerbation frequency, and mortality. These effects are accompanied by the improvement of lung function and quality of life. Asthma exacerbation often results in excessive bronchospasm, mucus production, and bronchial edema. Corticosteroid therapy can diminish bronchial vasculature and edema in asthma. In NHBE cells, 10 μg/mL Der p1-induced TEER increase was delayed and cytokine transcripts were decreased by steroid treatment. A previous study has reported that higher doses of house dust mite extracts can cause transient decreases in TEER, which may depend on cell-cell interactions. Barrier function disruption is consistent with our in vivo findings in mice sensitized and challenged with OVA. Nonetheless, gene silencing of claudin-4 decreased baseline TEER and prevented the Der p1-induced increase in TEER, supporting a possible role of claudin-4 in the regulation of epithelial barrier function. Surprisingly, claudin-4 genesilencing leads to an increase in cytokine transcripts in NHBE following Der p1 treatment. This suggests a role of epithelial claudin-4 other than the protection of barrier functions, i.e. modulation of PAMP-induced cytokine generation and regulation of inflammatory cell functions.

The limitations of this study are the recruitment of clinical samples not matched for smoking status or sex, and the lack of data on claudin-4 from in vivo studies. Further studies are needed to confirm our results.

In summary, our data revealed that plasma claudin-4 levels were inversely correlated to lung function, suggesting that clau-
Claudin-4 could be a marker for asthma inflammation and severity. Claudin-4 is altered in the epithelium from an OVA-sensitized/OVA-challenged asthma mouse model. A critical component of epithelial TJs and dysregulation of claudin-4 in the pulmonary epithelium can lead to cytokine release that in turn contributes to inflammatory cell activation and airway responsiveness. These effects can be repaired by steroid treatment. These findings thus raise the possibility that regulation of lung epithelial barrier proteins may constitute a therapeutic approach for asthma.

ACKNOWLEDGMENTS

This research was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) funded by the Ministry of Health & Welfare, Republic of Korea (HI15C2032) and Soon Chunhyang University Hospital.

REFERENCES

1. Harkness LM, Ashton AW, Burgess JK. Asthma is not only an airway disease, but also a vascular disease. Pharmacol Ther 2015;148:17-33.
2. Global Initiative for Asthma. Global strategy for asthma management and prevention 2014 [Internet]. [place unknown]: Global Initiative for Asthma; 2014 [cited 2016 Jun 3]. Available from: http://www.ginasthma.org/.
3. Park HW, Tantisira KG. Genetic signatures of asthma exacerbation. Allergy Asthma Immunol Res 2017;9:191-9.
4. Bossé Y, Paré PD, Seow CY. Airway wall remodeling in asthma: from the epithelial layer to the adventitia. Curr Allergy Asthma Rep 2008;8:357-66.
5. Benayoun L, Druilhe A, Dombret MC, Aubier M, Pretolani M. Airway structural alterations selectively associated with severe asthma. Am J Respir Crit Care Med 2003;167:1360-8.
6. Ebina M, Yaegashi H, Chiba R, Takahashi T, Motomiya M, Tanemura M. Hyperreactive site in the airway tree of asthmatic patients revealed by thickening of bronchial muscles. A morphometric study. Am Rev Respir Dis 1990;141:1327-32.
7. Wilson J. The bronchial microcirculation in asthma. Clin Exp Allergy 2000;30 Suppl 1:51-3.
8. Davies DE. Epithelial barrier function and immunity in asthma. Ann Am Thorac Soc 2014;11 Suppl 5:S244-51.
9. Park CS, Kim YH, Kang SY. Collection between RAST and skin test for inhalant offending allergens. Allergy Asthma Immunol Res 2017;9:191-9.
10. Adams KF, Schatzkin A, Harris TB, Kipnis V, Millikan RC, Bouder CK, et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med 2006;355:763-78.
11. Islam SA, Luster AD. T cell homing to epithelial barriers in allergic disease. Nat Med 2012;18:705-15.
12. Cookson W. The immunogenetics of asthma and eczema: a new focus on the epithelium. Nat Rev Immunol 2004;4:978-88.
13. Etwegeger T, Akdis CA. IL-33 links tissue cells, dendritic cells and Th2 cell development in a mouse model of asthma. Eur J Immunol 2011;41:1535-8.
14. Hammad H, Chieppa M, Perros F, Willart MA, Germain RN, Lambrecht BN. House dust mite allergen induces asthma via Toll-like receptor 4 triggering of airway structural cells. Nat Med 2009;15:410-6.
15. Georas SN, Rezaee F. Epithelial barrier function: at the front line of asthma immunology and allergic airway inflammation. J Allergy Clin Immunol 2014;134:509-20.
16. Schleimer RP, Kato A, Kern B, Kuperman D, Avila PC. Epithelium: at the interface of innate and adaptive immune responses. J Allergy Clin Immunol 2007;120:1279-84.
17. Tsukita S, Furuse M, Itoh M. Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol 2001;2:285-93.
18. Chen X, Gumbiner BM. Crosstalk between different adhesion molecules. Curr Opin Cell Biol 2006;18:572-8.
19. Reijula JP, Reijula KE. The impact of Finnish tobacco legislation on restaurant workers’ exposure to tobacco smoke at work. Scand J Public Health 2010;38:724-30.
20. Soini Y. Claudins in lung diseases. Respir Res 2011;12:70.
21. Kage H, Flodby P, Gao D, Kim YH, Marconnet CN, DeMaio L, et al. Claudin 4 knockout mice: normal physiological phenotype with increased susceptibility to lung injury. Am J Physiol Lung Cell Mol Physiol 2014;307:L524-36.
22. Koval M. Claudin heterogeneity and control of lung tight junctions. Annu Rev Physiol 2013;75:551-67.
23. Jin W, Rong L, Liu Y, Song Y, Li Y, Pan J. Increased claudin-3, -4 and -18 levels in bronchoalveolar lavage fluid reflect severity of acute lung injury. Respiratory 2013;18:643-51.
24. Lappi-Blanco E, Lelahoten SI, Sormunen R, Merikallio HM, Soini Y, Kaarteenaho RL. Divergence of tight and adherens junction factors in alveolar epithelium in pulmonary fibrosis. Hum Pathol 2013;44:895-907.
25. Moon KY, Lee PH, Kim BG, Park CS, Leikauf GD, Jang AS. Claudin 5 in a murine model of allergic asthma: its implication and response to steroid treatment. J Allergy Clin Immunol 2015;136:1694-1696.e65.
26. Reddel HK, Bateman ED, Becker A, Boulet LP, Cruz AA, Drazen JM, et al. A summary of the new GINA strategy: a roadmap to asthma control. Eur Respir J 2015;46:622-39.
27. Hammad H, Lambrecht BN. Barrier epithelial cells and the control of type 2 immunity. Immunology 2015;43:29-40.
28. Schlingmann B, Molina SA, Koval M. Claudins: gatekeepers of lung epithelial function. Semin Cell Dev Biol 2015;29:11-20.
29. Chae MC, Park CK, Jeon MH, Hwang I, Kwon KY, Jang BC. Prognostic significance of claudin 4 in completely resected adenocarcinoma of the lung. Korean J Thorac Cardiovasc Surg 2014;47:262-8.
30. Wan H, Winton HL, Soeller C, Tovey ER, Gruenert DC, Thompson PJ, et al. Der p1 facilitates transepithelial allergen delivery by disruption of tight junctions. J Clin Invest 1999;104:123-33.